HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Baak, J P A Articles by Mutter, G L Search for Related Content PubMed PubMed Citation Articles by Baak, J P A Articles by Mutter, G L Pubmed/NCBI databases Medline Plus Health Information Uterine Cancer

EIN and WHO94

¹ Department of Pathology, Stavanger University Hospital, 4068 Stavanger, Norway; Gades Institute, University of Bergen, Bergen, Norway; Free University, Amsterdam, The Netherlands
² The Brigham and Women Hospital, Harvard Medical School, Boston, Massachusetts, USA

Correspondence to:
Dr J P A Baak
Department of Pathology, Stavanger University Hospital, Armauer Hansens Road 20, 4068 Stavanger, Norway; baja@sir.no

Abbreviations: CAH, complex atypical hyperplasia; CH, complex hyperplasia; EH, endometrial hyperplasia; EIN, endometrial intraepithelial neoplasia; H&E, haematoxylin and eosin; SAH, simple atypical hyperplasia; SH, simple hyperplasia; VPS, volume percentage stroma; WHO, World health organisation

The first 150 words of the full text of this article appear below.

Endometrial hyperplasia is a common disease (at least 120 000 new cases each year in the European Union). The wide range of histological presentations of endometrial hyperplasia is accompanied by high intraobserver and interobserver variability in diagnostic classification. The overall risk of progression of hyperplasia to cancer is 5–10%, but this may vary substantially between individual patients according to the histological pattern. Unreliable diagnosis of hyperplasia translates into inappropriate treatment, either as a result of the undertreatment of high risk lesions or the overtreatment of low risk lesions, which leads to unnecessary suffering and high treatment costs.

Many different classification systems for endometrial hyperplasia have been proposed and used over the past few decades. Before 1985, such terms as "mild, moderate, and severe hyperplasia" were often used in the USA, whereas "cystic" and "adenomatous hyperplasia" was more fashionable in Europe. By 1982, confusion in terminology and disagreement in criteria between . . . [Full text of this article]

This article has been cited by other articles:

				W G McCluggage My approach to the interpretation of endometrial biopsies and curettings. J. Clin. Pathol., August 1, 2006; 59(8): 801 - 812. [Abstract] [Full Text] [PDF]